Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Ryan Fukushima sold 10,247 shares of Tempus AI stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total transaction of $645,765.94. Following the completion of the sale, the chief executive officer directly owned 652,216 shares of the company’s stock, valued at approximately $41,102,652.32. The trade was a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ryan Fukushima also recently made the following trade(s):
- On Monday, November 2nd, Ryan Fukushima sold 80 shares of Tempus AI stock. The shares were sold at an average price of $74.29, for a total transaction of $5,943.20.
- On Wednesday, September 16th, Ryan Fukushima sold 700 shares of Tempus AI stock. The shares were sold at an average price of $70.00, for a total transaction of $49,000.00.
- On Friday, August 21st, Ryan Fukushima sold 14,286 shares of Tempus AI stock. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00.
Tempus AI Price Performance
Tempus AI stock opened at $53.98 on Friday. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $89.09. The company’s 50 day moving average price is $72.79 and its two-hundred day moving average price is $57.55. The stock has a market cap of $9.85 billion, a P/E ratio of -50.92 and a beta of 3.61. The company has a quick ratio of 2.48, a current ratio of 2.61 and a debt-to-equity ratio of 2.70.
Top Tempus AI Stories
Investors following TEM have been watching these stories:
- Positive Sentiment: Tempus plans to present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium, which could increase visibility for its research and precision-medicine platform. Tempus to present 16 abstracts
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating
- Neutral Sentiment: Several senior executives, including the CEO and CFO, sold shares. The filings say the sales covered tax withholding obligations on vested equity awards, making them less indicative of a change in confidence, though multiple insider sales may still draw investor attention. Insider sale report
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on TEM shares. Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and upped their price objective for the company from $35.00 to $70.00 in a research note on Tuesday, November 3rd. Raymond James Financial set a $80.00 target price on Tempus AI in a research report on Wednesday, September 2nd. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $79.37.
View Our Latest Analysis on TEM
Institutional Investors Weigh In On Tempus AI
Several large investors have recently modified their holdings of the stock. Pictet Asset Management Holding SA increased its position in Tempus AI by 2,965.7% in the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after buying an additional 486,493 shares during the last quarter. Eagle Health Investments LP bought a new stake in shares of Tempus AI in the first quarter valued at $11,588,000. First Trust Advisors LP lifted its position in shares of Tempus AI by 90.3% during the 3rd quarter. First Trust Advisors LP now owns 456,624 shares of the company’s stock valued at $37,397,000 after buying an additional 216,692 shares during the last quarter. Aristotle Atlantic Partners LLC purchased a new position in shares of Tempus AI during the 1st quarter valued at $6,179,000. Finally, Public Sector Pension Investment Board purchased a new position in shares of Tempus AI during the 3rd quarter valued at $9,992,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.
About Tempus AI
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Tempus AI
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
